Heterogeneity in Signaling Pathway Activity within Primary and between Primary and Metastatic Breast Cancer

Márcia A. Inda 1,†, Paul van Swinderen 1,†, Anne van Brussel 2, Cathy B. Moelans 3, Wim Verhaegh 1,*, Hans van Zon 1, Eveline den Biezen 2, Jan Willem Bikker 4, Paul J. van Diest 3 and Anja van de Stolpe 2

1 Precision Diagnostics Department, Philips Research, 5656 AE Eindhoven, The Netherlands; marciainda@hotmail.com (M.A.I.); paul@vanswinderen.com (P.v.S.); hvanzon@gmail.com (H.v.Z.)
2 Philips Molecular Pathway Diagnostics, 5656 AE Eindhoven, The Netherlands; anne.brussel@philips.com (A.v.B.); eveline.den.biezen@philips.com (E.d.B.);anja.van.de.stolpe@philips.com (A.v.d.S.)
3 Department of Pathology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands; cmoelans@umcutrecht.nl (C.B.M.); p.j.vandiest@umcutrecht.nl (P.J.v.D.)
4 CQM, Consultants in Quantitative Methods, 5616 RM Eindhoven, The Netherlands; janwillem.bikker@cqm.nl
* Correspondence: wim.verhaegh@philips.com; Tel: +31-6-46722609
† These authors contributed equally to this work.

Simple Summary: Personalized breast cancer treatment with targeted therapy (e.g. tamoxifen or PI3K inhibitors) requires identification of responder patients. Phenotypical heterogeneity within the primary, and between primary tumor and metastases, may however interfere with response to therapy, if based on a single primary tumor biopsy. In this study, we investigated this heterogeneity, using novel assays to measure activity of tumor-driving signal transduction pathways, e.g. estrogen receptor and PI3K pathways, in multiple samples distributed across the tumor and in metastases. Within the primary tumor, heterogeneity was dominant at microscale (biopsy block) and not at macroscale (across tumor), suggesting that a single biopsy is generally representative for the whole primary tumor. The differences found between pathway activity in primary tumor and metastases suggests that it is recommendable to analyze pathway activity in metastatic samples for treatment selection for late stage patients.

Abstract: Targeted therapy aims to block tumor-driving signaling pathways and is generally based on analysis of one primary tumor (PT) biopsy. Tumor heterogeneity within PT and between PT and metastatic breast lesions may, however, impact the effect of a chosen therapy. Whereas studies are available that investigate genetic heterogeneity, we present results on phenotypic heterogeneity by analyzing the variation in the functional activity of signal transduction pathways, using an earlier developed platform to measure such activity from mRNA measurements of pathways’ direct target genes. Statistical analysis comparing macro-scale variation in pathway activity on up to five spatially distributed PT tissue blocks (n = 35), to micro-scale variation in activity on four adjacent samples of one PT tissue block (n = 17), showed that macro-scale variation was not larger than micro-scale variation, except possibly for the PI3K pathway. Simulations using a “checkerboard clone-size” model showed that multiple small clones could explain the higher micro-scale variation found for the TGFβ and Hedgehog pathways, and that intermediate/large clones could explain the possibly higher macro-scale variation of the PI3K pathway. While within PT, pathway activities presented a highly positive correlation, correlations weakened between PT and lymph node metastases (n = 9), becoming even worse for PT and distant metastases (n = 9), including a negative correlation for the ER pathway. While analysis of multiple sub-samples of a single biopsy may be sufficient to predict PT response to targeted therapies, metastatic breast cancer treatment prediction requires analysis of metastatic biopsies. Our findings on phenotypic intra-tumor heterogeneity are compatible with emerging ideas on a Big Bang type of cancer evolution in which macro-scale heterogeneity appears not dominant.
Keywords: tumor heterogeneity; signaling pathway activity; mRNA analysis; primary tumor; metastasis; breast cancer

1. Introduction
Cancer can be described in terms of abnormal functioning of one or more signal transduction pathways that control major cellular functions, e.g., cell division, differentiation, migration, and metabolism. Around 10–15 signal transduction pathways can drive growth and metastasis of breast cancer [1,2]. In cancer, they can be activated by receptor ligands or specific DNA mutations [3–11]. Signaling pathways are in principle clinically actionable, since their activity can be modified by certain drugs or other treatments. Treatment with targeted drugs is increasingly used in breast cancer, aiming to block the tumor-driving pathways in a (neo)adjuvant or metastatic setting [12]. However, predicting the effect of targeted therapy has generally proven to be very difficult [13]. One reason is that cancer genome mutation analysis does not sufficiently predict which signaling pathways are active in an individual tumor [13,14]. Furthermore, heterogeneity in signaling pathway activity may be present within a tumor, while targeted drug choice is usually based on analysis of a single primary tumor (PT) biopsy. Similar problems exist when choosing targeted therapy for treatment of patients with metastatic disease, where therapy choice is generally based on analysis of a tissue sample from the PT, although marked genotypic and phenotypic differences between PT and distant site (DS) metastases have been described [15,16]. Unfortunately, limited knowledge is available on heterogeneity in signaling pathway activity within a PT and between PT and lymph node (LN) and DS metastases [17,18]. One reason has been the lack of reliable assays to measure signaling pathway activity in formalin-fixed paraffin-embedded (FFPE) tissue samples used in routine diagnostic settings.

A novel analysis method was described before to quantify signaling pathway activity in cancer. Based on Bayesian models, the method infers a pathway activity score from transcription factor-specific target gene mRNA levels [19–22]. While originally developed for use on fresh frozen tissue samples, this method was recently adapted for use on FFPE material for a number of signaling pathways, i.e., androgen receptor (AR), estrogen receptor (ER), PI3K-FOXO, Hedgehog (HH), TGFβ and Wnt pathways [23–25]; see Supplementary methods (Figures S-M2 and S-M3). Using this approach, we analyzed heterogeneity in signaling pathway activity within breast PT and between PT and LN and DS metastases.

2. Materials and Methods
2.1. Study Design
The goal of this study was to investigate phenotypic heterogeneity within primary and between primary and metastatic breast cancer lesions, using a novel mRNA-based assay platform to measure the functional activity of relevant signal transduction pathways on multiple samples pertaining to the same patient. Within the primary tumor, heterogeneity was estimated at macro-scale and at micro-scale. Macro-scale heterogeneity analysis was performed on up to five spatially distributed PT tissue blocks from 35 primary breast cancers of various subtypes; micro-scale heterogeneity analysis was performed on four adjacent samples of a single tissue block from 17 matched PT. To investigate phenotypic heterogeneity between primary tumor and metastatic breast cancer lesions, samples from 9 PT with matched lymph node (n = 33) and 9 PT with distant metastatic sites (n = 12) were analyzed. Table 1 gives a summary description of the sample sets used in this study. A detailed description with the respective sample numbers per patient is given in supplementary data file S1. Measured pathway activity scores for all samples are given in supplementary data file S2.
Table 1. Summary description of sample sets used. The total number of patients and number of patients per subtype are given. Between brackets are the corresponding number of samples and their type; b: Primary tumor tissue block sample, PT: primary tumor sample, LN: lymph node metastasis sample, DS: distant site metastasis sample. Detailed description is given in the Supplementary Information (Supplementary Information, SampleCounts).

| Sample set | Description                                                                 | Total          | Per Breast Cancer Subtype | LumA | LumB | HER2 | TN |
|------------|------------------------------------------------------------------------------|----------------|----------------------------|------|------|------|----|
|            |                                                                              |                | Luma | Lumb | HER2 |        |     |
| I          | 1 to 5 block (b) samples from primary tumors                                | 18 (49 b)      | 8 (20 b) | 5 (15 b) | - | 5 (14 b) |
| II         | 2 to 5 block samples from primary tumors with 4 matched quadrant samples (per patient) | 17 (50 b)      | 9 (28 b) | 4 (12 b) | 1 (2 b) | 3 (8 b) |
| III        | Primary tumors (PT) and 1 to 3 matched distant metastasis samples            | 10 (9 PT/13 DS) | Subtyping not available |
| IV         | 9 patients from sample sets II and III                                       | 9 (33 LN)*     | 4 (20 LN) | 2 (3 LN) | 1 (1 LN) | 1 (8 LN) |

* Subtyping not available from one patient.

Archival samples were retrospectively collected under appropriate Dutch ruling and analyzed in a blinded manner; all tissue samples were formalin-fixed paraffin-embedded (FFPE). Breast cancer molecular subtyping was performed on surgically resected PT in a standard manner using the surrogate definitions from the 13th St Gallen International Breast Cancer Conference [26], based on ER, PR and HER2 protein staining (Figure 1A). Thus, in this study, the nomenclature Luminal A and B should be interpreted as Luminal A-like and Luminal B-like.

Figure 1. Analyzed primary breast cancer samples. (A) Pathology classification of analyzed primary breast cancers. Surrogate classification of Luminal A and Luminal B subtypes based on the surrogate definitions from [26], using ER/PR/HER2 immunohistochemistry staining. (B) Tissue samples analyzed from surgically resected primary tumors were either a tissue block sample or a quadrant sample. Tissue block samples were obtained by scraping one or more adjacent slides (depending on the amount of cancer tissue per slide) from each available FFPE tissue block. The tumor tissue area...
was annotated by a pathologist and tumor-containing areas were scraped from the slide(s) for RNA isolation. Quadrant samples were obtained from one randomly selected FFPE tissue block per patient. Sequential tissue slides were divided into 4 quarts, tumor areas annotated and tissue from the quarts scraped from the slides for RNA isolation. Care was taken to scrape only cancer tissue. To obtain similar amounts of tumor tissue, multiple adjacent slides were scraped until the same area of scraped tumor had been collected. (C) Typical example of a tissue block sample, showing how quadrant sample areas were divided. More examples are given in supplementary Figure S-M1.

2.2. Tissue Sample Sets

A variable number of tissue blocks, taken from different locations, was available per PT to investigate heterogeneity in pathway activity at the macro-scale. To investigate heterogeneity at the micro-scale, four adjacent “quadrant” samples from the same tissue block (one block per tumor) were made available for a subgroup of PT. To investigate variation in pathway activity between primary tumor and metastases, two separate patient sample sets were analyzed: one with multiple PT blocks matched with a variable number of LN metastasis samples, the other containing a single PT block and a variable number of metastasis samples from different DS.

2.3. Sample Preparation

Tissue slides were cut from the FFPE blocks at 10 μm thickness. The tumor area was annotated by an experienced pathologist and macrodissected, aiming at similar tumor tissue volumes for RNA extraction (Figure 1B–C and Figure S-M1). RNA was isolated from the annotated areas using standard procedures, as described in detail in the Supplementary methods.

2.4. Measuring Pathway Activity

Functional activity of signal transduction pathways was assessed using biologically validated computational pathway models as described before [19–21,25]. The approach uses mRNA levels of a number of a pathway’s direct target genes, which were selected based on extensive proof points from the literature, as increased levels of expression are direct evidence of activation of the respective pathways. Underlying the approach is a Bayesian computational model, as shown in supplementary Figure S-M2, which describes (i) how the expression of the target genes depends on the activation of the respective transcription complex, and (ii) how qPCR results depend in turn on the expression of the respective target genes. After calibration of the model parameters using samples with a known ground truth status of pathway activity, the activity of a new test sample can be assessed by feeding its mRNA measurements in the bottom nodes of the network and applying Bayesian reasoning to determine the odds that the pathway was activated or not. After a logarithmic transformation and normalization, this yields a pathway activity score on a 0–100 scale, where 0 corresponds to the lowest and 100 corresponds to the highest odds in favor of an active pathway that a specific model can theoretically infer.

The pathway activity assays were originally developed on data from Affymetrix HG-U133Plus2.0 (Thermo Fisher, Waltham, MA, USA) microarrays but have been converted to qPCR mRNA measurements as input, to enable use of FFPE material [25]. Typically, per pathway, a slightly smaller subset of about 12 target genes were used, and models were recalibrated on qPCR measurements. For details, see the supplementary methods (Figures S-M2 and S-M3) and [23,24]. Next to pathways’ direct target genes, a panel of reference genes was used for normalization purposes.

In our study, we used qPCR pathway assays for the AR, ER, PI3K, HH, TGFβ and Wnt pathways, available on the FIPA Pathway Plate 1.0 (Philips Molecular Pathway Diagnostics, Eindhoven, The Netherlands). As such, these represent relevant hormone-driven pathways (AR and ER), growth factor pathways (PI3K), and stem cell-related pathways (HH, TGFβ and Wnt), which play a role across different breast cancer subtypes. PI3K pathway activity is based on the inverse activity of the measured FOXO transcription factor activity score, on the premise that no cellular oxidative stress is present; for this
reason, the FOXO activity score is interpreted in combination with SOD2 target gene expression level to distinguish between growth control- and oxidative stress-induced FOXO activity, as described before [20,27].

2.5. Statistical Data Analysis

Due to the heterogeneous sample set, we used linear mixed models [28,29] to enable the best possible quantification and statistical underpinning of the pathway analysis results. In view of readability, only a brief overview of the statistical approach is given here; for an extensive description, including detailed analysis results, we refer to the Supplementary statistics. The model used to analyze heterogeneity in primary breast cancer subtypes considers patients grouped by cancer subtype classification, with multiple tumor block measurements per patient. The pathway activity score of a given pathway is modeled as (Figure 2A):

$$y_{pq} = \mu_t + \alpha_p + \beta_{pq}.$$  (1)

Here, $y_{pq}$ is the pathway activity score of patient $p$ for tumor block $q$; $\mu$ is the average of scores in this subtype classification group $t$ (e.g., LumA or LumB); $\alpha_p$ is a random contribution of the patient tumor as a whole, compared to the group average (assumed normally distributed around zero with standard deviation $\sigma_{\text{pat}}$); and $\beta_{pq}$ is the random contribution of block $q$ which is used to accommodate tumor heterogeneity for patient $p$ (assumed normally distributed around zero with standard deviation $\sigma_{\text{block}}$). The value $\sigma_{\text{block}}$ describes the spread of scores within a single patient tumor (the tumor heterogeneity) for patients in a specific breast cancer subtype $t$ and $\sigma_{\text{pat}}$ describes the variation between individual patients, regardless of the breast cancer subtype they belong to.

**Figure 2.** Schematic representation of models used for data analysis. (A) Model used for estimation of variation in signaling pathway activity between breast cancer subtypes ($y_{pq} = \mu + \alpha_p + \beta_{pq}$). (B) Extended model enabling additional comparison between variation at micro-scale and macro-scale. ($y_{pve} = \mu_t + \alpha_p + \beta_{pbe} + \varepsilon_{pbe}$). The models have random contributions that are added to each other; the random character of each level of contribution is indicated by a Gaussian distribution with standard deviation (σ) and example realizations from that distribution. The models describe the pathway activity scores $y_{pb}$ and $y_{pbe}$ as a sum of contributions. Starting from the average score $\mu_t$ (computed for each breast cancer subtype $t$ separately, with $t$ being Luminal A, Luminal B, or ER negative), a patient-specific contribution $\alpha_p$ (red arrows) and a block-specific contribution $\beta_{pb}$ (green arrows) are added to the average signaling pathway activity score ($\mu$). In the extended model, an additional contribution $\varepsilon_{pbe}$ (blue arrow) is added to the pathway activity score of each block, to model the possibility of quadrant-to-quadrant heterogeneity (see Figure 1B for block and quadrant definitions).

The measured pathway activity scores, in combination with this statistical model structure, are used for the statistical estimation of the parameters like $\sigma_{\text{block}}$ or $\sigma_{\text{pat}}$. Since they are fitted parameters to the data, the models provide a confidence interval for these quantities. For the analysis performed with quadrant measurements, the model was
extended to accommodate and estimate additional micro-scale heterogeneity. The model used has an additional layer that enables taking both the tissue block and the quadrant sample measurements into account (Figure 2B):

\[ y_{pq} = \mu + \alpha_p + \beta_{pq} + \varepsilon_{pq}. \]  

(2)

Macro-scale heterogeneity (from blocks) and micro-scale heterogeneity (from quadrants) are defined in terms of parameters of this model. Analysis was performed in STATA (StataCorp, College Station, Tx, USA, 2017, Release 15 [28]) and R (www.r-project.org) using nlme and emmeans packages [29–31]. For details, see Supplementary statistics.

3. Results

3.1. Signal Transduction Pathway Activity in Primary Breast Cancer Subtypes

To investigate heterogeneity in the activities of the ER, AR, PI3K-FOXO, HH, TGFβ, and WNT signaling pathways, we analyzed samples from up to five spatially distributed PT tissue blocks from 35 patients with breast cancers of various subtypes (Table 1 sample sets I and II). For this analysis, pathway activity scores were available from Luminal A, B, and ER-negative (ER−) tumors; see Figure 1 and the Materials and Methods section for a description of the subtype classification and tissue sample sets. Mean pathway activity score values per patient categorized by breast cancer subtype are presented in Figure 3A. An overview of all measured pathway activity scores is given in supplementary data file S2. Figure 3A shows that the ER pathway had the broadest range in activity scores and largest separation in scores between subtypes. ER pathway activity scores were similar between Luminal A and Luminal B PT, but markedly lower in ER− patients. FOXO pathway activity scores (as an inverse readout for PI3K pathway activity) and TGFβ pathway activity scores were higher in Luminal A and progressively lower in Luminal B and ER− cancers, indicating the lowest PI3K pathway activity in Luminal A tumors. WNT pathway activity scores were higher in ER− cancers compared to Luminal type (Figure 3A, Supplementary statistics, Table S-S1 and S-S2).
Figure 3. Variation in signaling pathway activity score per breast cancer subtype in the tissue block samples of sample sets I and II. (A) Distribution of scores for Luminal A (lumA), Luminal B (lumB), and HER2-positive/triple negative breast cancer (ER−). Each point represents the average pathway activity score across all tissue block samples of a patient. The HER2-driven patient sample is depicted as a small red triangle. Tukey adjusted significance levels of pairwise test for equality of means are indicated (***, *: p < 0.0001, *: p < 0.05, values in Supplementary statistics, Table S-S1). (B) Estimated standard deviation (SD) with corresponding 95% confidence intervals (95% CI) of signaling pathway activity scores describing the heterogeneity in activity scores between all patients, irrespective of subtype (pat) and within a single tumor for tumors in a specific breast cancer subtype (block lumA, block lumB, block ER−), based on pathway activity scores of primary tumor tissue block samples (values in Supplementary statistics, Table S-S3). (C) Estimated ratios of between patient SD to within tumor SD (σpat / σblock) with corresponding 95% confidence intervals for subtype-independent σblock model. Significance levels are indicated (*: p < 0.05, values in Supplementary statistics, Table S-S4 and S-S5).

3.2. Variance Explained Per Model Parameter

Subsequently, we estimated the statistical variation in pathway activity between patients and within the same tumor (Figure 3B–C) using the model illustrated in Figure 2A and Supplementary statistics (Figure S-S1 and Table S-S3). For all signaling pathways, the variation in pathway activity within a single tumor for patients in a specific subtype (σblock,t, for t = LumA, LumB, or ER−) was comparable for all breast cancer subtypes (Figure 3B, Supplementary statistics, Table S-S3). This implies that there is no need to compute a separate standard deviation (σblock,t) for each subtype. Instead, a simpler model could be used in our subsequent analysis, in which the estimate for the spread of scores within a single tumor is the same regardless of subtype (i.e., replacing σblock,t by σblock). Further analysis, using this simpler model (Supplementary statistics, Table S-S5), indicated that the variance in pathway activity score between patients (σpat) is larger than the variance within a single tumor (σblock) for the WNT and ER pathways (i.e., σpat/σblock > 1), while both variances were comparable for the remaining pathways (Figure 3C, Supplementary statistics, Table S5).

3.3. Variation in Pathway Activity Within a Single Tumor in Primary Breast Cancer

To compare the variation of scores at macro-scale to the variation at micro-scale, pathway activity scores measured in the four quadrant samples obtained from a single FFPE block (micro-scale), as well as in all tissue blocks (macro-scale), were analyzed (sample set II, 17 patients, see Table 1 and Figure 4). Figure 4A illustrates the range and variation of pathway activity scores measured in all tissue blocks and quadrant samples of sample sets I and II (Table 1). Figure 4B depicts the spread between pathway activity scores measured in the 4 quadrant samples (micro-scale) versus the spread in scores measured in the multiple tissue blocks of the same tumor (macro-scale). Figure 4C correlates the averaged value for pathway activity of the quadrant samples and the respective matched tissue block sample. While variation in pathway activity was observed between quadrant samples and between tissue blocks of the same tumor (Figure 4B), the averaged pathway activity scores of the quadrants strongly correlated with both the score of the matched tissue block and with the average scores of the tissue blocks (Table S-S8).
Figure 4. Heterogeneity in signaling pathway activity score within primary tumors at micro- and macro-scale (sample sets I and II). (A) Pathway activity scores for tissue block (blue) and quadrant (red) samples of each patient. Ranges are presented as vertical lines; individual scores are presented as triangles. (B) Spread in signaling pathway activity scores from quadrant samples (horizontal lines) vs. spread in scores from tissue block samples of the same patient (vertical lines). Significance level for the correlation between mean scores of tissue block samples versus mean scores of quadrant samples (point where horizontal and vertical lines cross) are indicated in the figure by stars (*: p < 0.05, **: p < 0.01, ***: p < 0.001, corresponding values are in Table S-S8). (C) Correlation between mean quadrant sample pathway activity score and score of the corresponding tissue block sample. Stars indicate the significance level of the correlations (corresponding p values are in Table S-S8). (B–C) Diagonal black lines illustrate a one-to-one relation. Samples of the same patient have the same color. Black lines illustrate a one-to-one relation. (D) Ratio between macro-scale and micro-scale standard deviation (SD) of signaling pathway activity scores; $\sigma_{macro}/\sigma_{micro}$ measured in tissue block samples and quadrant samples, respectively. Variances computed using the macro- vs. micro-scale model (Figure 2B, Supplementary statistics, Figure S-S2, Table S-S6) using all samples (top) or those with less technical noise (leaving out all samples with average Cq values > 31 for the reference genes used for the qPCR measurements). Significance level of Wald test p-value for comparing the ratio $\sigma_{macro}/\sigma_{micro}$ to 1 are indicated by stars (p values for model run using all samples in Supplementary Statistics, Table S-S7). (E) Summarized macro (block level) and micro-scale (quadrant level) heterogeneity per patient by taking the square root of the average variance across the six pathways, where an average SD of 10 means an average confidence interval of about 40 points. (F) Checkerboard visualization of a primary cancer, explaining differences in heterogeneity between micro-scale and macro-scale measurements of pathway activity. Left: Squares represent (small) cancer cell clones with variable pathway activity scores, simulated by grey (high pathway activity) and white (low pathway activity). For example, analyzing HH pathway activity in a randomly localized “tissue” sample (analogous to the tissue block samples) results in a smoothed averaged pathway activity, due to canceling out of variations in pathway activity that are present in areas smaller than the sampled area. On the other hand, when taking four quadrant samples, the varying pathway activity...
scores in the quadrants are measured, resulting in a higher measured pathway activity heterogeneity at micro-scale. Right: Quadrangles represent large cancer cell clones, with variations in pathway activity scores. In this case, it is expected that more heterogeneity will be found at the macro-scale, since the quadrants are more likely to have the same pathway activity. This might be the case for the PI3K-FOXO pathway. For detailed information on the associated statistical model, see Supplementary statistics.

To determine whether pathway activity varied more at macro-scale (tissue blocks) or at micro-scale (block quadrants), we calculated the ratio between the standard deviation of pathway activity score at the macro-scale and the standard deviation of pathway activity score at the micro-scale for each signaling pathway. The standard deviations were estimated using the model illustrated in Figure 2B (details in Supplementary statistics, Figure S-S2, Tables S-S6 and S-S7). For the AR, HH, TGFβ and Wnt pathways, variation in pathway activity score was significantly higher at the micro-scale than at the macro-scale, with the highest statistical significance for the HH pathway, $p < 0.001$ (Figure 4D, Supplementary statistics, Table S-S7). For the ER and FOXO pathways, the variation in score at the macro-scale was comparable to the micro-scale. Summarizing the macro (block level) and micro (quadrant level) heterogeneity per patient by taking the square root of the average variance across the six pathways also shows a higher variation at the micro-scale than macro-scale (Figure 4E). The median value across patients is 3.2 and 3.8 at the block level and quadrant level, respectively.

Extensive noise analysis was performed to identify technical noise, which might have biased the pathway activity scores, and therefore, the ratio between variation at macro-scale and micro-scale (Supplementary Methods, technical noise analysis, Figures S-M4–S-M6). High qPCR Cq values, which were more frequent in measurements of very small samples, may be associated with increased technical noise. Removal of such samples resulted in loss of significance of the higher variation in AR and Wnt pathway activity at micro-scale but did not change the results for the HH and TGFβ pathways (Figure 4D bottom). Taking this into account, we can safely draw an overall conclusion that heterogeneity in signaling pathway activity was not larger at the macro-scale (blocks) than at the micro-scale (quadrants), except for the PI3K-FOXO pathway for which a higher variation at macro-scale could not be excluded, based on the 95% confidence interval computed when the high qPCR Cq values had been removed (Figure 4D bottom). Variation in ER pathway activity was similar at micro-scale and macro-scale and variation in HH and TGFβ pathway activity was higher at micro-scale.

3.4. Variation in Signaling Pathway Activity at Micro-Scale Versus Macro-Scale

Since the observed higher variation in HH and TGFβ pathway activity on micro-scale compared to macro-scale seemed counter-intuitive, a hypothetical computational checkerboard model was developed to help explain observed results (Figure 4F, Supplementary statistics, Figure S-S3 and Figure S-S4). In this checkerboard model, squares represent cancer cell clones with variable pathway activity scores, depicted in grey and white, which are present across a tumor. In case cancer clones are smaller than the tissue block and around the size of the quadrant samples (Figure 4F, left), the pathway activity scores measured in (all) the tissue block samples will average out the varying pathway activity scores measured in the quadrant samples, causing the variance between tissue blocks to be smaller than the variance between quadrants. This is likely to be the case for the HH and TGFβ pathways for which the activity scores were found to dominantly vary between the quadrants of a block. Variation in ER pathway activity was relatively small and more or less similar across the whole PT. This can be explained by either a homogeneous tumor, or variations in ER pathway activity at a very small scale (very small “clones” with varying ER pathway activity; Figure 4F middle) across the whole tumor. In this case, the quadrant samples are larger than the clones with varying ER pathway activity and the differences in score between quadrants and between tissue block samples are similar. Finally, clones that are larger than the sampled blocks and
quadrants but much smaller than the whole tumor (Figure 4F, right) could explain the potentially higher variation at the macro-scale in PI3K-FOXO pathway activity. A detailed explanation is provided in the Supplementary statistics.

3.5. Differences in Pathway Activity Between Primary Tumors and Matched Lymph Node Metastases

To examine whether pathway activity in LN metastasis is similar to pathway activity in PT, multiple PT and LN matched samples per patient were analyzed (nine patients, PT tissue blocks from a subset of sample sets II and III, LN samples from sample set IV, see Table 1 and supplementary data file S1). For all signaling pathways, activity scores within the PT were positively correlated with pathway activity scores in corresponding LN metastases (Figure 5A). However, correlations were much smaller than the correlations obtained when comparing PT block and matched quadrant samples, ranging from 0.448, 95%CI (−0.308, 0.857), p = 0.2, for the TGFβ pathway to 0.825, 95%CI (0.356, 0.962), p = 0.006, for the HH pathway (Table S-S8). This indicates that pathway activity measured in PT may not reflect well the pathway activity measured in the corresponding LN metastasis.

Figure 5. Heterogeneity in signaling pathway activity between primary tumor and metastases (A) Correlation between measured pathway activity scores in primary (x-axis) tumor and matched lymph node metastases (y-axis) visualized by plotting pathway activity scores (Sample sets IV and II/III). (B) Correlation between measured pathway activity score in primary tumor (single sample) and matched distant metastases (Sample set III). Per plot, colors indicate samples that belong to one patient (patient IDs indicated in the legends), the cross indicates the average, and the black line is a visual guide for a one-to-one relation. Significance level for the correlation between mean scores are indicated by stars (*: p < 0.05, **: p < 0.01, corresponding values are in Table S-S8).

Quantitative differences in pathway activity score between LN metastatic samples and PT samples were calculated by comparing, for each patient p with matched PT and LN metastatic samples, (a) the delta in pathway activity score between each lymph node metastasis and the average score of the respective PT samples, Δp,LN, and (b) the delta in score between each PT tissue block and the respective PT block averages, Δp,block (Supplementary statistics, Figure S-S5). For all pathways, the spread in Δp,LN was larger than the spread in Δp,block, indicating that difference between PT and LN metastases was larger than the variation in pathway activity within the PT (Supplementary statistics, Tables S-S8, S-S9). For the TGFβ and FOXO pathways, activity scores were generally lower in lymph node metastases compared to the PT, with lower FOXO indicating higher PI3K pathway activity; for AR, HH and WNT pathways, activity scores were more frequently higher in lymph node metastases compared to the PT (Figure 5A, Supplementary statistics, Tables S-S8, S-S9, S-S10).
3.6. Differences in Pathway Activity Between Primary Tumors and Matched Distant Metastases

For this analysis, a single PT sample (per patient, \( n = 9 \)) matched with a variable number of DS metastatic samples was available (sample group III). Except for the TGF\( \beta \) pathway, correlations between DS metastasis and matched PT were worse than correlations between LN metastasis and matched PT. Correlations remained positive for FOXO and the HH and TGF\( \beta \) pathways, but became negligible for the AR and WNT pathways, and negative for the ER pathway, ranging from positive correlation of 0.601, 95% CI (−0.105, 0.904), \( p = 0.09 \) for the HH pathway to a negative correlation of −0.359, 95% CI (−0.826, 0.401), \( p = 0.3 \), for the ER pathway (Figure 5B, Table S8).

To further examine the differences in pathway activity score between distant metastases and PTs, for each patient \( q \) with matched PT and DS metastatic samples, deltas in activity score between each DS metastatic sample and the one available matched PT sample, \( \Delta q_{\text{meta}} \), were compared to the previously computed PT tissue block deltas, \( \Delta p_{\text{block}} \) (Supplementary statistics, Figure S-S6–S-S8, Tables S-S8, S-S9, the indices \( q \) and \( p \) emphasize the use of two different patient cohorts). Here again, the spread in \( \Delta q_{\text{meta}} \) was larger than the spread in \( \Delta p_{\text{block}} \) for all pathways, indicating that, as with LN metastasis, differences in pathway activity scores between PT and DS metastases are larger than the variation within the PT (Supplementary statistics, Tables S-S8, S-S9). While a loss of AR, ER and TGF\( \beta \) pathway activity was frequently observed in metastases compared with the PT, WNT pathway activity was regularly increased in metastases (Figure 5B, Supplementary statistics, Tables S-S8, S-S9).

3.7. Comparing Pathway Activity Between Lymph Node and Distant Metastases

Variation between distant metastases and lymph node metastases were analyzed by comparing the spread in \( \Delta q_{\text{meta}} \) to the spread in \( \Delta p_{\text{LN}} \). Apart from the TGF\( \beta \) pathway, variation between distant metastases (spread in \( \Delta q_{\text{meta}} \)) was larger than variation between lymph nodes (the spread in \( \Delta p_{\text{LN}} \), Supplementary statistics, Tables S-S8, S-S9).

3.8. Pathway Activity Related to Metastatic Organ Site

Specific tissues are thought to provide a favorable niche for metastatic growth that is driven by a signaling pathway for which the activating ligand is provided by the tissue niche [32]. The small number of metastatic samples from a similar organ site precluded investigation of a relation between signaling pathway activity and metastatic location. Given this limitation, pathway activity scores in individual metastatic tumors may still provide interesting information. Wnt pathway activity score was highest in bone (\( n = 2 \)) and ileum (\( n = 1 \)); HH pathway activity was highest in ovarian, ER pathway activity highest in a brain, and TGF\( \beta \) highest in a skin and a bone metastatic lesion (see supplementary data file S2).

3.9. PI3K-FOXO Pathway Analysis

For only three patients, all triple negative subtype, FOXO activity was high in combination with elevated SOD2 expression level, indicating oxidative stress-associated FOXO activity, precluding direct inference of PI3K pathway activity (Supplementary methods, Figure S-M7, [20]). For all other analyzed samples, PI3K pathway activity could be directly (inversely) inferred from the respective FOXO activity score.

4. Discussion

To investigate variation in tumor-driving signaling pathway activity within primary breast cancer tumors and between matched primary tumor and LN and DS metastases, activity of the PI3K growth factor pathway, the ER and AR hormonal pathways, and the developmental Wnt, HH and TGF\( \beta \) pathways was measured at multiple locations in PT as well as in metastatic samples. Pathway activity scores were quantified using a novel method for signaling pathway analysis, adapted for FFPE samples [19–21]. While initial
semi-quantitative analysis of the various groups of pathway measurement results already indicated our major findings [33], the complex relationships between the available sample sets required an innovative statistical model-based data analysis approach to objectively quantify our results [29].

4.1. Variation in Pathway Activity Between Breast Cancer Subtypes

As expected, based on previous work, ER pathway activity was mostly defined by the breast cancer subtype and scores were much higher in PT of Luminal A and B patients, compared to ER− tumors [19,23]. More interesting is that within Luminal A and B subtypes, activity of the ER pathway showed a large dynamic range. We previously showed that ER protein expression is a prerequisite, but not sufficient, for functional activity of the ER pathway, and the current results further confirm this [19]. In the absence of activating mutations in the ER gene, the presence of ER ligands and specific downstream proteins (e.g., cofactors) determine the actual activity of the ER transcription factor. This creates the necessity to measure the functional activity of the ER pathway to optimally predict sensitivity to hormonal therapy [23,34]. The highest activity scores of the FOXO transcription factor, which is associated with an inactive PI3K pathway, were found in Luminal A cancers. This is in agreement with our earlier findings and with the known tumor-driving role of the ER pathway, in the absence of PI3K pathway activity, in this subtype [20].

4.2. Within Tumor Heterogeneity of Signaling Pathway Activity

To the best of our knowledge, to date, no information is available on phenotypic heterogeneity within primary breast cancer with respect to functional signaling pathway activity. Knowledge on signaling pathway heterogeneity is limited to studies on variations in ER and HER2 IHC staining, and on spatial variations observed in specific gene mutations and copy number changes across the tumor [17,18,35–38]. However, this does not provide information on variations in functional signaling pathway activity. In the current study, with a possible exception of the PI3K pathway, such pathway activity variation was found be comparable both at the macro-scale, across the primary tumor, and at the micro-scale, within a single tumor tissue block.

The HH and TGFβ pathway showed consistently higher variation in activity at the micro-scale. Both pathways are typically active in stem cells, suggesting that multiple small clones may be present and spread throughout the PT and composed of cancer stem cells. This fits well with the cancer stem cell hypothesis, which assumes that small groups of relatively quiescent cancer cells that have acquired stem cell characteristics are present in tumor tissue [1,39,40]. Both pathways are generally thought to play an important role in governing metastatic behavior and therapy resistance of cancer stem cells, another hallmark of cancer [1]. Previous pathway analysis, using the same pathway activity measurement approach, suggested that overt HH pathway activity, measured in a standard tissue slide, was associated with a worse prognosis [41]. In the current study, no outcome data were available, preventing further investigation of the prognostic role of activity of this signaling pathway at the micro-scale.

For the ER pathway, variation in pathway activity within the PT was lower than for the other pathways, and similar at the micro-scale versus macro-scale. The variation within the primary tumor was also relatively small compared to the variation in ER pathway activity between individual luminal A/B patients. These observations can be readily explained by considering the ER pathway as the prime tumor-driving pathway in luminal breast cancer, in contrast to HER2 and triple negative cancer subtypes. Variations in ER immunohistochemistry (IHC) staining within an ER positive primary tumor have been reported, but not related to pathway activity [36]. ER-activating estrogens are expected to distribute relatively evenly in tissue, which is compatible with only small differences in pathway activity as we observed before [35,42,43].
4.3. A “Checkerboard” Clone-Size Cancer Model and “Big Bang” Type of Cancer Evolution

Our observation that, with the possible exception of the PI3K-FOXO pathway, the variation in pathway activity was generally not larger at the macro-scale than micro-scale, and for the HH and TGFβ pathways, even higher at the micro-scale, is compatible with currently emerging ideas on a Big Bang type of cancer evolution based on genomic analysis of PT, in which macro-scale heterogeneity appeared to be not the dominant form [17]. Compatible with this model, the presented “checkerboard” model for cancer heterogeneity can be used to explain our findings in terms of variable cancer cell clone sizes, all spread more or less evenly across the tumor: the smallest “clones” or cancer cell areas with slightly varying ER pathway activity; small clones that have an active HH and/or TGFβ pathway, and possibly intermediate/large clones with varying PI3K pathway activity. In such a model, combined ER and PI3K pathway active clones may be more rapidly proliferating, while HH and TGFβ pathway active clones are “neutral”, less proliferative, and may have a stem cell character.

4.4. Variation in Pathway Activity Between Primary and Lymph Node Metastases

Subsequently, we investigated whether pathway analysis of the primary tumor could predict pathway activity in metastatic tumors. While pathway activity scores between quadrant samples of a single block, and between blocks of one PT showed highly significant correlations, correlations decreased between PT and LN metastases and significance was lost. The lowest correlation was found between PT and DS metastases. These results provide interesting new information about breast cancer metastasis. Since LN metastatic samples were spatiotemporally close to the PT, a closer relation to the PT was expected compared to the DS metastases that are spatiotemporally further away. The PI3K pathway is generally thought to be an important metastasis-driving pathway in addition to its general role as a tumor “survival” pathway, explaining the relatively strong correlation in activity between PT and LN metastases [44]. The observed higher variation in pathway activity between DS metastases compared to LN metastases is probably due to LN representing a singular type of metastatic niche, while DS metastases grow in all kinds of organ niches with their respective variations in the microenvironment, including ligand availability for the various signaling pathways [45,46]. As a few tentative examples to illustrate this, Wnt ligand availability may have caused the one intestinal metastatic tumor to have the highest Wnt pathway activity score, while local Sonic Hedgehog ligand availability may have induced the high HH pathway activity score in the ovarian metastatic lesion [32,47,48]. For the ER pathway, such heterogeneity has also been demonstrated in ER-positive breast cancer patients [49].

Interestingly, a negative correlation was present for ER pathway activity between PT and DS metastases. Since only ER-positive luminal patients were included in this part of the study, a number of patients probably had received adjuvant hormonal therapy, potentially resulting in selection for ER pathway-inactive metastases [50]. Unfortunately, lack of treatment information precluded further analysis of this relationship between treatment and ER pathway activity.

Obvious limitations of the study were the relatively limited patient and sample numbers, and lack of clinical treatment and outcome data. Despite this, to the best of our knowledge, the study is unique in allowing a quite detailed comparison between signaling pathway activity scores within a PT and between PT and metastases.
5. Conclusions

The clinically relevant conclusions that can be drawn suggest that heterogeneity with respect to pathway activity within a single biopsy may generally be representative for the whole tumor, with the possible exception of the PI3K pathway, while variation in ER pathway activity is relatively small within the PT compared to that seen between luminal breast cancers from different patients. We cannot exclude that for the PI3K pathway, multiple spatially separated biopsies may be required to obtain a sufficiently complete picture of this pathway’s activity pattern across the tumor. Pathway activity scores found in the PT predicted activity in LN metastases to some extent, especially with respect to the PI3K-FOXO pathway. Prediction of pathway activity in DS metastases is no longer realistic, also in view of the large variation between metastases in different organ locations. If possible, taking biopsies from multiple metastatic locations may, therefore, be preferred when considering targeted therapy for metastatic disease, to choose the most effective (targeted) drug or drug combination.

In view of its high clinical relevance, especially with respect to targeted treatment in (neo)adjuvant and metastatic settings, the current findings should be confirmed in subsequent clinical studies. We recommend that a confirmation study should: (1) optimize standardization of tissue sampling; (2) note size of the tumor and location of the sample taken in the 3D space of the tumor, to reduce the influence of variable microenvironment, e.g., oxygen concentration, immune cell infiltrate, etc.; (3) use similar amounts of cancer cells to extract RNA from. Importantly, application and further development of the statistical models that we introduced should help to improve quantification of cancer evolution and the resulting tumor heterogeneity, necessary to objectively compare clinical studies and bring the field forward. We believe that such studies will further complement knowledge on tumor evolution and the resulting tumor heterogeneity, enabling improvement in choosing the most effective therapy for patients with breast cancer.

Supplementary Materials: The following are available online at www.mdpi.com/2072-6694/13/6/1345/s1. The supplementary statistics file includes: Figure S-S1: Diagram of heterogeneity between subtype classification model; Figure S-S2: Diagram of the macro- and micro-scale model implementing linear mixed models with three layers; Figure S-S3: Checkerboard model for cancer clones; Figure S-S4: Checkerboard model simulated standard deviation as a function of relative sample size; Figure S-S5: Lymph node metastases and matched primary tumor model; Figure S-S6: Distant metastases and matched primary tumor model; Figure S-S7: Comparison of frequency counts of the lymph node metastasis sample-specific contributions; Figure S-S8: Comparison of percent frequency counts of the metastatic sample-specific contributions; Table S-S1: Pairwise test for equality of means for $\mu_{\text{LumA}}$, $\mu_{\text{LumB}}$, and $\mu_{\text{ER}}$; Table S-S2: Average activity score ($\mu$) estimates for the subtype-dependent $\sigma_{\text{block}}$ model; Table S-S3: Standard deviation ($\sigma_{\text{Pat}}$ and $\sigma_{\text{block}}$) estimates for the subtype-dependent $\sigma_{\text{block}}$ model; Table S-S4: Average activity score ($\mu$) estimates for subtype-dependent $\sigma_{\text{block}}$ model; Table S-S5: Standard deviation ($\sigma_{\text{Pat}}$ and $\sigma_{\text{block}}$) estimates and $\sigma_{\text{Pat}}/\sigma_{\text{block}}$ ratio estimates for the subtype-independent $\sigma_{\text{block}}$ model; Table S-S6: Macro- and micro-scale model standard deviations ($\sigma$ parameter) estimates; Table S-S7: Macro- and micro-scale model derived parameters; Table S-S8: Correlation between signaling pathway activity scores within PT and between PT and LN or DS metastasis; Table S-S9: Mean and standard deviation computed for $\Delta_{q,\text{block}}$, $\Delta_{q,\text{LN}}$, and $\Delta_{q,\text{meta}}$; Table S-S10: differences between means and ratios between standard deviations for the various pathway models. The supplementary methods file includes: Figure S-M1: Example slides for scraping, where tumor areas have been annotated and divided into four quadrants; Figure S-M2: Structure of the Bayesian networks used to model the transcriptional program of signaling pathways; Figure S-M3: Conversion of the Affymetrix ER pathway model to qPCR pathway model; Figure S-M4: Comparison between the estimated qPCR-related technical noise variance and the model variance as estimated by the statistical model; Figure S-M5: Ratio between macro-scale and micro-scale standard deviation (SD) of signaling pathway activity scores; Figure S-M6: Comparison between amounts of RNA which were isolated from tissue samples, for quadrant and block samples; Figure S-M7: Verification of inverse FOXO-PI3K readout. Supplementary data files are: Data file S1—Sample counts: Tables describing the type and number of samples taken per patient; Data file S2—Sample sets: Tables with measured pathway activity scores per sample.
Author Contributions: Conceptualization, P.J.v.D. and A.v.d.S.; Formal analysis, M.A.I., P.v.S., A.v.B., W.V., J.W.B. and A.v.d.S.; Investigation, A.v.B., C.B.M., H.v.Z. and E.d.B.; Methodology, M.A.I., W.V., H.v.Z., E.d.B. and J.W.B.; Resources, C.B.M. and P.J.v.D.; Writing—original draft, M.A.I., P.v.S., P.J.v.D. and A.v.d.S.; Writing—review and editing, A.v.d.S. and W.V. All authors have read and agreed to the published version of the manuscript.

Funding: None of the authors have received funding for their contribution in this project.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki. Ethical review and approval were waived for this study, since it was conducted on rest material in accordance with the Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands (https://www.federa.org/code-goed-gebruik-van-lichaamsmateriaal-2011).

Informed Consent Statement: Patient consent was waived under the GDPR scientific research exemption.

Data availability Statement: Pathway activity scores and associated info used in the analyses are given in supplementary data file S2.

Acknowledgments: We wish to thank Paul van de Wiel for the very useful comments and suggestions.

Conflicts of Interest: Márcia A. Inda, Paul van Swinderen, Anne van Brussel, Wim Verhaegh, Hans van Zon, Eveline den Biezen, and Anja van de Stolpe are (former) employees of Philips. The other authors declare no potential conflict of interest. Patents and patent filings on the reported pathway models are held by Koninklijke Philips NV.

References
1. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
2. Van de Stolpe, A. On the origin and destination of cancer stem cells: A conceptual evaluation. Am. J. Cancer Res. 2013, 3, 107–116.
3. Mangelsdorf, D.J.; Thummel, C.; Beato, M.; Herrlich, P.; Schütz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; et al. The nuclear receptor superfamily: The second decade. Cell 1995, 83, 835–839.
4. Sever, R.; Glass, C.K. Signaling by Nuclear Receptors. Cold Spring Harb. Perspect. Biol. 2013, 5, a016709.
5. Katzenellenbogen, B.S.; Frasor, J. Therapeutic targeting in the estrogen receptor hormonal pathway. Semin. Oncol. 2004, 31 (Suppl. 3), 28–38.
6. Taiapale, J.; Beachy, P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001, 411, 349–354.
7. Lum, L.; Beachy, P.A. The Hedgehog response network: Sensors, switches, and routers. Science 2004, 304, 1755–1759.
8. Katoh, Y.; Katoh, M. Hedgehog target genes: Mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med. 2009, 9, 873–886.
9. Nusse, R.; Clevers, H. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell 2017, 169, 985–999.
10. Coffler, P.J.; Burgersing, B.M.T. Forkhead-box transcription factors and their role in the immune system. Nat. Rev. Immunol. 2004, 4, 889–899.
11. Burgersing, B.M.T. A brief introduction to FOXOlogy. Oncogene 2008, 27, 2258–2262.
12. Dancey, J.E.; Bedard, P.L.; Onetto, N.; Hudson, T.J. The genetic basis for cancer treatment decisions. Cell 2012, 148, 409–420.
13. Massard, C.; Michiels, S.; Ferté, C.; Le Deley, M.-C.; Lacroix, L.; Hollebecque, A.; Verlingue, L.; Ileana, E.; Rosellini, S.; Ammari, S.; et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 2017, 7, 586–595.
14. Marquart, J.; Chen, E.Y.; Prasad, V. Estimation of the Percentage of US Patients with Cancer Who Benefit From Genome-Driven Oncology. JAMA Oncol. 2018, 4, 1093–1098.
15. Schrijver, W.A.M.E.; Selenica, P.; Lee, J.Y.; Ng, C.K.Y.; Burke, K.A.; Piscuoglio, S.; Berman, S.H.; Reis-Filho, J.S.; Weigelt, B.; van Diest, P.J.; et al. Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. Cancer Res. 2018, 78, 3112–3121.
16. Schrijver, W.A.M.E.; Suijkerbuijk, K.P.M.; van Gils, C.H.; van der Wall, E.; Moelans, C.B.; van Diest, P.J. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. J. Natl. Cancer Inst. 2018, 110, 568–580.
17. Sottoriva, A.; Kang, H.; Ma, Z.; Graham, T.A.; Salomon, M.P.; Zhao, J.; Marjoram, P.; Siegmund, K.D.; Press, M.F.; Shibata, D.; et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 2015, 47, 209–216.
18. Sun, R.; Hu, Z.; Curtis, C. Big Bang Tumor Growth and Clonal Evolution. Cold Spring Harb. Perspect. Med. 2018, 8, a028381.
19. Verhaegh, W.; van Ooijen, H.; Inda, M.A.; Hatzis, P.; Versteeg, R.; Smid, M.; Martens, J.; Foekens, J.; Van De Wiel, P.; Clevers, H.; et al. Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways. Cancer Res. 2014, 74, 2936–2945.

20. van Ooijen, H.; Hornsveld, M.; Dam-de Veen, C.; Velter, R.; Dou, M.; Verhaegh, W.; Burginger, B.; van de Stolpe, A. Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model. Ann. J. Pathol. 2018, 188, 1956–1972.

21. Van de Stolpe, A.; Holtzer, L.; van Ooijen, H.; de Inda, M.A.; Verhaegh, W. Enabling precision medicine by unravelling disease pathophysiology: Quantifying signal transduction pathway activity across cell and tissue types. Sci. Rep. 2019, 9, 1603.

22. Verhaegh, W.; van de Stolpe, A. Knowledge-based computational models. Oncotarget 2014, 5, 5196–5197.

23. Inda, M.A.; Blok, E.J.; Kuppen, P.J.K.; Charebbili, A.; den Biezen-Timmermans, E.C.; van Brussel, A.; Fruytier, S.E.; Kränenberg, E.M.-K.; Kloet, S.; van der Burg, S.; et al. Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer. Mol. Cancer Ther. 2020, 19, 680–689.

24. Van Brussel, A.; Inda, M.A.; Den Biezen, E.; van Strijp, D.; Wrobel, J.; van Ooijen, H.; Hoffmann, R.; Verhaegh, W.; van de Stolpe, A. Assessing functional Androgen Receptor (AR) pathway activity using a computational model. Ann. Oncol. 2017, 28 (Suppl. 5), 1697p.

25. Van de Stolpe, A.; Verhaegh, W.; Blay, J.-Y.; Ma, C.X.; Pauwels, P.; Pegram, M.; Prehen, H.; Ruyscher, D.D.; Saba, N.F.; Slovin, S.F.; et al. RNA based approaches to profile oncogenic pathways from low quantity samples to drive precision oncology strategies. Front. Genet. 2021, 11, 598118.

26. Goldhirsh, A.; Winer, E.P.; Coates, A.S.; Gelber, R.D.; Piccart-Gebhart, M.; Thürlimann, B.; Albain, K.S.; André, F.; Bergh, J.; et al. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 2013, 24, 2206–2223.

27. Van de Stolpe, A. Quantitative Measurement of Functional Activity of the PI3K Signaling Pathway in Cancer. Cancers 2019, 11, 293.

28. StataCorp, L.L.C. Command mixed (Multilevel mixed-effects linear regression). In Multilevel Mixed-Effects Reference Manual Release 15; Stata Press: College Station, TX, USA, 2017; pp. 513–568.

29. Pinheiro, J.; Bates, D. Mixed-Effects Models in S and S-PLUS; (Statistics and Computing); Springer-Verlag: New York, NY, USA, 2000.

30. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, 2017. Available online: https://www.R-project.org/ (accessed on 11 March 2021).

31. Lenth, R.V. Least-Squares Means: The R Package lsmmeans. J. Stat. Softw. 2016, 69, 1–33.

32. Degirmenci, B.; Valenta, T.; Dimitrieva, S.; Hausmann, G.; Basler, K. GLI1-expressing mesenchymal cells form the essential Wnt-secreting niche for colon stem cells. Nature 2018, 558, 449–453.

33. van de Stolpe, A.; van Brussel, A.; Moelans, C.; Inda, M.A.; Verhaegh, W.; den Biezen, E.; van Diest, P. Measuring functional signal transduction pathway activity on breast cancer tissue samples to determine intra-tumor heterogeneity and heterogeneity between primary and metastatic tumors. Cancer Res. 2018, 78 (Suppl. 13), 3690.

34. Heldring, N.; Pike, A.; Andersson, S.; Matthews, J.; Cheng, G.; Hartman, J.; Tujague, M.; Ström, A.; Treuter, E.; Warner, M.; et al. Estrogen receptors: How do they signal and what are their targets. Physiol. Rev. 2007, 87, 905–931.

35. Yang, S.-R.; van de Stolpe, A.; van Brussel, A.; van Ooijen, H.; Galimzianova, A.; Cohn, D. Does hormone expression by IHC predict ER pathway activity? An analysis in a metastatic breast cancer patient cohort. In Proceedings of the 2018 San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 4–8 December 2018; AACR: Philadelphia, PA, USA; Cancer Res. 2018, 79 (Suppl. 4), P5-11-06.

36. Davis, B.W.; Zava, D.T.; Locher, G.W.; Goldhirsh, A.; Hartmann, W.H. Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur. J. Cancer Clin. Oncol. 1984, 20, 375–382.

37. Annaratone, L.; Simonetti, M.; Wernersson, E.; Marchiò, C.; Garnerone, S.; Scalzo, M.S.; Bienko, M.; Chiarle, R.; Sapino, A.; Crosetto, N. Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization. Oncotarget 2017, 8, 18680–18698.

38. Pertschuk, L.P.; Axiotis, C.A.; Feldman, J.G.; Kim, Y.-D.; Karavattayhayil, S.J.; Braithwaite, L. Marked Intra-tumoral Heterogeneity of the Proto-Oncogene Her-2/neu Determined by Three Different Detection Systems. Cancer Res. 1999, 5, 369–374.

39. Dittmer, J. Breast cancer stem cells: Features, key drivers and treatment options. Eur. J. Cancer Clin. Oncol. 2019, 55, 59–74.

40. Cho, I.-J.; Lui, P.P.; Obajdin, J.; Riccio, F.; Stroukov, W.; Willis, T.L.; Spagnoli, F.; Watt, F.M. Mechanisms, Hallmarks, and Implications of Stem Cell Quiescence. Stem Cell Rep. 2019, 12, 1190–1200.

41. Beachy, P.; Cai, S.; Ma, Y.; Hatakeyama, J.; Zhao, C.; Stoffels, M.; Verhaegh, W.; van de Stolpe, A.; Pegram, M. Targeted disruption of transcriptional effector GLI2 attenuates breast tumor growth and metastasis. Cancer Res. 2018, 78 (Suppl. 4), P5-03-11.

42. Cantley, L.C.; Hunter, T.; Sever, R.; Thorner, J.W. (Eds.) Signal Transduction: Principles, Pathways, and Processes; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2014.

43. Katzenellenbogen, J.A.; Mayne, C.G.; Katzenellenbogen, B.S.; Greene, G.L.; Chandarlapaty, S. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nat. Rev. Cancer 2018, 18, 377–388.
44. Cantley, L.C. The phosphoinositide 3-kinase pathway. *Science* **2002**, *296*, 1655–1657.
45. Shibue, T.; Weinberg, R.A. Metastatic colonization: Settlement, adaptation and propagation of tumor cells in a foreign tissue environment. *Semin. Cancer Biol.* **2011**, *21*, 99–106.
46. Sleeman, J.P. The lymph node pre-metastatic niche. *J. Mol. Med.* **2015**, *93*, 1173–1184.
47. Szkandera, J.; Kiesslich, T.; Haybaeck, J.; Gerger, A.; Pichler, M. Hedgehog signaling pathway in ovarian cancer. *Int. J. Mol. Sci.* **2013**, *14*, 1179–1196.
48. Ray, A.; Meng, E.; Reed, E.; Shevde, L.A.; Rocconi, R.P. Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells. *Int. J. Oncol.* **2011**, *39*, 797–804.
49. Nienhuis, H.H.; van Kruchten, M.; Elias, S.G.; Glaudemans, A.W.J.M.; de Vries, E.F.J.; Bongaerts, A.H.H.; Schröder, C.P.; de Vries, E.G.E.; Hospers, G.A.P. 18F-Fluorooestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. *J. Nucl. Med.* **2018**, *59*, 1212–1218.
50. Gonzalez-Angulo, A.M.; Morales-Vasquez, F.; Hortobagyi, G.N. Overview of resistance to systemic therapy in patients with breast cancer. *Adv. Exp. Med. Biol.* **2007**, *608*, 1–22.